Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

(2010) Youn H. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study

(2009) John A. Thompson et al.   Clinical Genitourinary Cancer

The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer

(2009) M. Ray et al.   ONCOLOGIST

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Christian Manegold et al.   JOURNAL OF CLINICAL ONCOLOGY

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE